Ready-to-surge ASX firm could ‘rewind’ muscular injuries…HALT the symptoms of ageing…
And has just struck a partnership deal with the biggest pharmaceutical firm in the world!
**An announcement about their first project could come ANY DAY NOW and send its share price on a huge UPSURGE**
If you want to steal in for a potential 748%
profit – make your move now!
Dear Reader,
This deal is going down with or without you.
A potential 748% return from what could soon be one of the most in-demand companies on the planet.
Aussie punters who move now could make a stack out of this ready-to-blow situation.
Whether or not YOU are counting the cash 12 months from now alongside them…well, that depends on how closely you pay attention here.
This stock has been on my radar for a while.
Its science-fiction-like technology has promised to solve the single biggest problem we face as a species…something that has been written about, dreamed of and hoped for since the first ape walked upright.
Something that could mean injuries, neurological diseases and even AGEING ITSELF soon becomes a thing of the past.
But it’s always seemed too far off. A distant possibility even in today’s era of breakthrough technology.
NOW all that has changed. An imminent mega-partnership with a $300 billion pharma giant has moved it from ‘amber’ to…‘get your money in pronto!’
The deal puts this 45¢ small-cap at the centre of a $191 billion market. A market that holds within it the promise to make debilitating injuries a thing of the past. There’s no way for you to claim all of the money on the table. But I can show you how you could possibly siphon off a $37k share of it with just a $5k investment today.
That’s a 748% return on your money. That’s the potential I see here.
Eli Broad, the only person to ever build TWO Fortune 500 companies, has said of this tech breakthrough:
‘Without a doubt [it] will lead to the dramatic improvement in the human condition and will benefit millions of people.”
Biotech investing expert and author George Wolff believes this tech means
‘…the effects of many catastrophic diseases can be reversed. The damaged brains of Alzheimer’s disease patients might be restored. Severed spinal cords may be re-joined. Damaged organs may be rebuilt.’
What I’m writing to you about today represents a milestone on the road toward this incredible future.
What’s in the works between one tiny Aussie stock and one of the biggest medical giants on the planet may revolutionise the way we think about getting older…the lasting effects of injuries…and even the human lifespan.
But there’s one catch…
You have to get in NOW to stand a chance at banking the maximum possible upside.
An announcement about the inaugural project between this ASX minnow and the world’s biggest pharma company is OVERDUE. The anticipation leading up to the project could drive the stock price higher and higher. And then the opportunity will be BLOWN for you.
In 2014 I saw biotech stock OncoMed shoot up 150% in just two months on the back of a deal like this.
This imminent move will be much bigger, in my view. But the OncoMed deal shows you the speed with which you need to move to give yourself the best chance to profit.
My advice: jump in NOW!
I’ve already given my readers the name of the company.
They’ve got my full analysis of why I think a potential 748% profit is about to be triggered. And a full breakdown of everything at stake.
Now I want to get that information in your hands.
So let me show you what’s going on…
‘The Age of Immortality’
has arrived
In 1513, famed explorer Juan Ponce De León led an expedition to the island of Bimini in search of ‘The Fountain of Youth’.
As incredible as it might seem now, it was widely expected that he would find ‘a magical spring whose waters would rejuvenate those who drank from it.’
For hundreds of years the notion of an elixir that could wind back the clock of ageing has been left to the realm of the imagination.
But with the sequencing of the first genome…we have learned more about the human body in the last 40 years than in the previous four thousand years combined.
Once again, scientists have begun to investigate the possibility of pausing or even reversing the ageing process…
‘Enough advancements in ageing science have been made to lead us to believe it’s plausible, it’s possible, it’s been done for other species and there is every reason to believe it could be done in us.
‘This would be the most important medical intervention in the modern era, an ability to slow ageing.’
Dr Jay Olshansky, of the University of Illinois Chicago
Anyone past the age of 40 who has ever looked in the mirror or gotten out of bed with an aching lower back has whispered it to themselves…(be honest with yourself — YOU have wished too…)
‘If only I could turn back the clock 10 years…20 years… if only I could look, and feel, and BE young again!’
Today I want to show you that this burning human desire to live drastically longer could become a reality.
It is no longer a distant dream.
The final frontier: have anti-ageing scientists unlocked
the biggest medical breakthrough of all time?
And in my experience, when new technology solves a pervasive social problem, it’s could prove a gold mine for investors...
For example, when the Sydney-based medical device company Cochlear Limited [ASX: COH] developed an implant to help restore hearing…it experienced a searing and sustained growth surge.
Today it holds over two-thirds of the worldwide hearing implant market…since 2000 it has ascended 1,055%.
And all my research tells me that the NEXT blockbuster ‘solution industry’ is going to be age-reversal.
The great news is, at the heart of this emerging megatrend is a tiny Australian company…one with the vision and breakthrough technology to make tangible age-reversal a reality.
Their imminent project with a pharma giant will give this visionary company practically unlimited funds to make their world-changing technology available to millions of people.
If you can’t yet sense why I’m so excited…why I’m pounding this keyboard as fast as I can to get this message to you…
Here’s why….
‘Biotechnology will stop ageing’
Ray Kurzweil, Head of Google X
Is it REALLY possible?
I don’t blame you if you’re totally sceptical. Because advances like this seem impossible — right up until they happen.
For example, smallpox accounted for an estimated 300–500 million deaths in the 20th century.
To those who lived through that period, it must have seemed like it would always be around.
But thanks to medical technology — in the form of a vaccination — by 1979 the World Health Organisation certified that smallpox had been ERADICATED.
Our biggest challenges can be defeated.
Over the last few years there have been some astonishing, never-thought-possible breakthroughs in biotechnology…
From re-growing limbs…to curing forms of cancer…to what can reversing symptoms of MS and Parkinson’s…to womb transplants!
20 years ago procedures like this were the stuff of dreams. Today they are changing lives.
To those who aren’t clued up on break-out tech, these advancements may still seem like science fiction…or magic. But as famed futurist and author Arthur C. Clarke once said…
‘Any sufficiently advanced technology is indistinguishable
from magic.’
The kinds of innovations we’re seeing seem impossible at first…but they are happening.
And they are driving us toward a future in which…
We could ‘switch off ’ ageing
Just look at the advances going on all around us…
- Adding 25 years to our life-span:
Scientists at the Salk Institute in the US are reprogramming cells to ‘reverse age-related hallmarks’. Ultimately, these tests on animals could result in extending the human life-span by 30%.
‘Our study shows that ageing may not have to proceed in one single direction… ageing might be reversed.’
Dr Juan Carlos Izpisua Belmonte,
a professor in Salk's Gene Expression Laboratory
- Gene therapy breakthrough: ‘We’ve made history’
CEO of BioViva Elizabeth Parrish has targeted muscle-depletion to stave off the signs of ageing. In April 2016, she announced a patented method of lengthening the average human lifespan by 20 years.
- Turning the ageing ‘switch’ OFF:
The biggest breakthrough so far came last year. Japanese researchers have discovered the ‘fountain of youth gene’ that may be capable of turning the ageing process on and off. On 12 October, the Nobel Prize committee awarded the 2016 prize for Physiology or Medicine to the Japanese Professor Yoshinori Ohsumi. Ohsumi’s work centred on the process of autophagy — the means by which cells’ unnecessary components are destroyed and recycled.
- Regenerating the brain:
Researchers at the University of California San Francisco are developing antibodies that could wind-back the effects of an ageing protein. Targeting this ‘old age protein’ could assist to reverse memory loss and regenerate the brain.
- World’s first anti-ageing drug:
The Food and Drug Administration in the US have given the green light to trial a first-of-its-kind drug to humans. Originally intended to treat diabetes, the drug could one day allow doctors to no longer fight individual diseases like cancer, Alzheimer’s and dementia…but instead target the underlying problem — ageing itself:
‘“If you target an ageing process and you slow down ageing then you slow down all the diseases and pathology of ageing as well,” he said “That’s revolutionary. That’s never happened before.’
‘…“But there is every reason to believe it’s possible. The future is taking the biology that we’ve now developed and applying it to humans. 20 years ago ageing was a biological mystery. Now we are starting to understand what is going on.”’
Professor Gordon Lithgow of the Buck Institute for Research on Ageing
in California, as reported by the Telegraph (emphasis is mine)
I could show you 20, 30, 50 more trials and breakthroughs going on right now.
The point is, this is an industry exploding into life. And it is big business, too.
- Google, through its anti-ageing company Calico, has already committed $1.5bn to developing anti-ageing research and treatments.
- Famed entrepreneur Peter Thiel (founder of PayPal) gave $3.5m to start the Methuselah Foundation, which is focused on uncovering promising life-extension therapies.
- Venture Capitalist Bill Maris invested 36% of the fund’s assets, which total nearly $2bn, into companies that can slow ageing, improve longevity and reverse disease.
- Craig Venter — the man who helped decode the genome — has founded an organisation called Human Longevity Inc, raising at least $70m to help ‘change the face of ageing’.
And companies are beginning to erupt from this rampant wave of research and investment…
Advanced biotech stocks like Medivation (up 3,151% since 2010)…
Aspex Pharma (up 472% since 2012)
And ResApp Health (up 4,542% since 2015)…
Any one of these companies would have turned a grub-stake of $800 into a life-changing fortune.
But that’s just half of this incredible story.
Yes this sector is being bombarded with capital from billionaires…
Yes, anti-ageing stocks are going through the roof…
And YES I have selected a stock for you that I believe could ultimately outstrip all of these gains.
But I got in touch today because it is on the cusp of commencing a landmark project with one of the biggest pharma stocks on the planet.
Let me show you what this deal could mean for its share price.
150% gain in just TWO months
When a small company strikes a deal with a huge player in an erupting industry…the price of the stock could really take off.
It’s like unleashing a huge wave of energy into the company.
Its revenue surges up.
Its public profile surges up.
And investment into the company surges up with it.
If you already have a stake in the firm, it could unlock a huge profit for you.
Why? Because the moment the deal hits the financial newswires, analysts start reporting on the stock…financial advisers start recommending it to their clients…and the wider market gets interested and rushes in to take a punt on the company.
Get in before that rush, and the rewards could be eye-watering.
Here, let me show you…
Celgene and OncoMed: 150% gain in just two months!
Celgene is a global bio-pharma company. One of the big players in this white-hot sector.
In December 2013 it struck a deal with a (then) tiny biotech stock called OncoMed.
Over the following TWO months, OncoMed’s stock soared more than 150%.
Source: Bloomberg
When these partnerships are announced, the trigger effect could take your stake to breathless highs.
Let’s look at another example…
Johnson & Johnson and Halozyme: 164% gain in just seven months!
In December 2014, industry monolith J&J announced a partnership with biotech minnow Halozyme.
J&J paid $581m for the use of the company’s proprietary drug-delivery system.
The newswires lit up. And again, the price surge was astonishing…
Source: Bloomberg
Now let’s look at another profit triggered by a mega-deal…
Hoyo Group and Clean TeQ Holdings: 116% gain in eight months!
When ASX-listed resource and mineral purification company Clean TeQ struck a deal with Chinese giant Hoyo Holdings, it was a bonanza for investors.
Their June 2016 partnership in a joint water purification venture in Shanxi Province was worth $81m.
You can guess what happened next:
Source: Bloomberg
(My readers were doubly pleased. I already had this stock in my buy list. The stock is up over 2,000% since I tipped it.)
OK, I could give you 20 more examples. But you get the point. When the market becomes aware of these lucrative partnership projects, their antennae start twitching…and their impulse to BUY becomes irresistible.
As you know, past performance doesn’t tell us what will happen in the future. You can’t rely on it to make sound investment decisions. The above examples simply illustrate that these deals have the capacity to trigger explosive price action.
Ride that buying frenzy and you will no longer be dreaming about making life-changing money from your stocks…you could be counting it!
And you won’t have to wait long…
Signed, sealed and ready to rocket
As I’ve just shown you, when a visionary company teams up with an industry giant, the share price could shoot to nose-bleed highs.
And the company I’ve selected could be about to feel the full benefit of this powerful investment phenomenon…
In the first few weeks of 2017, a deal was put in place for a partnership with a $303 billion pharma giant.
This deal is signed and sealed. BUT their partnership project doesn’t kick off until the end of Q1.
That’s now.
That means an announcement about this project is OVERDUE.
Typically, anticipation starts to build ahead of these types of events. Eager investors and financial newswires start buzzing.
And that’s when an explosive up-move could unfold.
It’s also when rumours start floating around about potential takeovers.
While there is nothing set in stone here…this could be the first inklings of such a deal. What could that mean for investors who get in now?
Well, put it this way: I have NEVER seen a takeover that hasn’t resulted in a short, sharp rise in the stock price.
This announcement could come ANY DAY NOW. Wait even a few hours, and you risk being too late to the party.
The only way to make sure you are in the running for ALL the potential profits on the table is to make your move NOW.
Source: Bloomberg
The pilot project with this pharma giant hasn’t commenced yet — so that gives you A VERY BRIEF window to steal in and stake your money.
If you want to catch it, the countdown is on. You can’t wait on this one. That’s the long and short of it. This is a situation where I believe the investors that think and move quickly will be best rewarded…
Because this industry is on the cusp of an eruption.
The anti-ageing market is estimated to be worth US$191bn within TWO years. That makes it one of the fastest growing sectors on the planet.
Take a step back.
How hard do you really need to be convinced about this? We’re talking about a NEW sector that can make people feel young again…that could possibly eradicate the symptoms of ageing…that could add 20, 30, even 50 healthy years to our lifespan…
It’s going to go ballistic!
My name, by the way, is Sam Volkering.
For the last decade it’s been an obsession of mine to hunt down tech stocks on the point of eruption. My research has taken me to four continents and I’ve witnessed some of the most breathtaking technological breakthroughs of the modern age.
The field of age reversal could be the most impactful tech opportunity I have yet come across.
And for profit-hungry investors, it’s everything you’re looking for. And more!
I believe that the companies within this rapidly growing biotech sector could make early investors flat-out rich.
In fact, they already are.
Innate Immunotherapeutics: UP 700% between Jan 2016 and Jan 2017!
- This Australian biotech pioneer is developing products to use the human immune system to defeat life-threatening diseases.
MiMedx Group: UP 630% over the last five years
- This regenerative medicine firm uses bioimplants (amniotic tissue, bone and skin) to help the body heal itself.
Regeneron Pharmaceuticals: UP 616% over the last five years
- One of the world’s most innovative companies, according to Forbes… Regeneron are innovating cures to many of the diseases and ailments that plague us as we age: colon cancer, arthritis, cholesterol and asthma.
Biospecifics Technology Corp: UP 1,180% over the past 10 years
- BioSpecifics is developing advances in collagen and scar tissue…a therapy with limitless application in repairing the bones, muscles and organs within our bodies.
These are pioneering anti-ageing companies making enormous, pioneering profits.
You can never be 100% certain a stock is going to lift-off in price; that’s impossible. So you are taking a risk when you invest your money. That’s true of any stock you put your spare capital into.
But as I have shown you, hitching on to a stock penning a massive deal with a sector giant puts the odds hugely in your favour.
That’s why I’ve locked on to this revolutionary anti-ageing firm.
I believe it is the number one pick in this erupting sector right now…the NEXT stock on the verge of ignition…a company that I believe could multiply your stake almost EIGHT TIMES OVER.
But I must make this very clear: this company has a project with one of the biggest pharma giants in the world looming.
When their pilot project kicks off…this 45¢ stock could catch fire.
That’s when the wider market could GATECRASH this story and send it two, three or four times higher in a flash.
If you are still on the outside, sitting on the side lines wondering if you should have a punt…sorry, you’ll be out of bang out of luck!
If you want to lock-in a potential 748% profit that I believe is on the cards. You are going to have to make a decision today.
Now, let me briefly run you through why this breakthrough company has been targeted by its $330bn ‘big brother’….
The 45¢ Perth firm ‘re-booting’
the human body
It’s happening right on your doorstep.
Not in some far-flung lab in Beijing or California. But right here in Perth.
It doesn’t just work on painkillers or vaccines. This goes way beyond all that.
This firm is developing procedures to repair the human body at the cellular level, and even grow new organs.
It has actually developed a way to reverse the degenerative process.
Think about that for a moment…
This radical tech doesn’t just slow down the rate at which parts of our bodies degenerate. It winds back that process — creating a virtual ‘fountain of youth’.
Using breakthrough stem cell therapy, this tiny Aussie company is changing the way we think of disease...even life itself.
Imagine going for a jog and twisting your knee. A horrible injury. One that could take up to 12 months of rehabilitation.
This company has developed a way to rewind the injury. Not just knee problems. But all joints, muscles, tendons, ligaments — the lot.
The implications of this tech mean that you could be running along the beach at the age of 90 years old, leaving your great grandson out of breath!
When people talk about the potential of ‘living forever’ or extending the human lifespan to 200…it usually conjures up ideas of another 50–70 years of inactivity, sitting in an arm chair watching telly.
But this company is capable of rejuvenating injured and ageing body parts so that we can enjoy decades of fit and healthy life.
Talk about world-changing biotech!
‘A biological time-machine’
What if you could reverse an injury? Literally, rewind the damage?
Take the body back to BEFORE a problem occurred?
As someone who blew out his shoulder playing Aussie Rules as a younger man, I’d certainly be keen!
Well, as far-fetched as it sounds, that’s exactly what this small stock is already doing.
Its leading product is already in advanced clinical trials.
The doctor applies a local anaesthetic, takes a tendon biopsy, cultivates the stem cells, and then re-injects the cultured cells into the site of the tendon injury.
This effectively replaces injured areas with ‘pre-injured’ muscle.
Patients can be in and out of the clinic in a matter of hours. They spend around $3,200 per session — and 95% of patients only need one injection before they see results (with only minimal side effects such as mild discomfort).
This is revolutionary treatment.
It provides unprecedented levels of pain relief, and dramatic improvements in tendon function.
It is a turning point in the treatment of muscular injuries.
And believe it or not, this industry-changing technique is just ONE of this company’s breakthroughs:
- It’s developing a lower cost, more effective stem cell treatment for cartilage regeneration in the knees…already striking a lucrative royalty based licensing deal with a key player in the gigantic Chinese health market.
- Also in clinical trials is a revolutionary method of repairing damaged eardrums. This therapy is still in the early stages of testing but the potential for a therapy that could possibly reverse deafness and severe ear damage is colossal.
- And one of its latest products is a collagen scaffold used for tissue repair and reconstruction. As we get older, our body invariably breaks down. This technique is designed to constantly ‘patch-up’ our weak spots…bones, muscle and organ tissue. It could even have further application in a treatment for brain repair and diseases like Alzheimer’s. This would open up the opportunity to tap a market worth $13 billion annually.
This is a gaping, lucrative market, begging to be tapped…
Grabbing just 0.1% of this
$191 billion market could send
this stock into ORBIT
The Alliance of Regenerative Medicine reports that stem cell therapy products generated revenue of over US$900 million in 2012, with 160,000 patients receiving treatments.
But the way I see it, this small company’s target market is much larger than that.
According to forecaster Transparency Market Research, the global market for orthopaedic implants was worth US$29.2 billion in 2012. The firm expects this market to grow to US$41.2 billion by 2019.
It is cheaper, less invasive and more effective than many of its competitors.
Beyond that, the ultimate potential is even larger.
It’s gargantuan.
According to Transparency Market Research, the overall anti-ageing sector will be worth $191 billion in just two years.
And they have just taken a huge step toward achieving significant market penetration with this looming partnership with a pharma giant.
So, let’s be conservative and imagine this small company could capture just a tenth of 1% of this market by the end of 2019.
That would be just 0.1% market penetration in the next two to three years.
Right now, you can pick this company up for just 45 cents a share.
Over the next three years, you could potentially see that climb to $3.56.
That’s a searing 748% up-kick in price.
That means a modest punt of $800 right now could make you almost $6k.
And a more substantial stake of $5k could pat off to the tune of $37,400!
Of course, there are risks here, too.
Like anything you put your money in, you could lose it. No-one can foresee if an even better technique will come two or three years down the line. I can only make an analysis on the way things stand today. And my research tells me it is ahead of its rivals and ready to ignite.
There are other risks to factor in, of course. The biotech industry is on a tear right now, but you cannot assume with 100% confidence that will continue. Further risks could be research funding issues or the failure of future clinical trials. These risks are inherent to investing in breakthrough biotech firms.
So yes, there are risks to consider here. But risk means different things to different people.
The word 'risk' derives from the early Italian riskcare, which means 'to dare'.
In this sense, risk is a choice rather than a fate. And that’s the way I see it when you take a punt on a stock like this…if it comes off you stand to make a tremendous amount of money.
If it doesn’t, then you are at least the master of your own destiny, giving yourself a chance at making a radical improvement to your investing returns.
I’ve put this company through my rigorous checklist, and I think its chances of executing its business plan and becoming a leader in stem cell therapy are extremely high.
And the new deal with a pharma giant stacks the odds even more in its favour.
From where I stand, this is a fantastic opportunity for you to potentially multiply your money many times over.
Everything I’ve just shown you ticks all the boxes:
- Pioneering biotechnology
- Leading the market
- Huge potential for future sales
- Sitting in a RAPIDLY growing, niche industry
As an investor, you should be wiping the drool off your keyboard by now.
And, of course, an irresistible catalyst is fast approaching…
I believe shares in this firm are on the cusp of a 748% surge. And that’s just the next few years. There’s really no telling just how much the share price could balloon if things pan out as I expect.
Source: Bloomberg
So, if you’re ready to jump in on this stock, all you need is a special report I’ve put together for you called ‘Ignition point 2017: How you could make 748% from the ASX medical time machine’
In the report I’ll show you my full research on this break-out stock…and a full risk analysis…so that you are clued up on every aspect and have a 360 degree view of this ready-to-erupt opportunity.
I want to get this report in your hands in the next five minutes.
It’s time to raid the ASX for potential triple and quadruple digit gains!
Taking a punt on a stock like this could fundamentally alter the course of your life.
And I should know; I’ve made it my career-long obsession to hunt down smaller, break-out companies and show Aussie investors how to get in EARLY.
A lot of people sit in bed at night and wonder what they’d do with a couple of million bucks. To them it will always be a dream. A little game they play before they drift off to sleep. These are the types that dream of winning the lottery without even buying a ticket!
Well, stuff that.
While they’re living in a fantasy world — you could be racking up real money.
For the past four years, I’ve been working here at Port Philip Publishing helping people do just that, profiting from break-out stocks.
In Australian Small-Cap Investigator, I scour the market for companies with the most explosive potential. And I share them with regular investors like you.
As you can see by some of their comments here, investing this way has the capacity to change your life…and transform your wealth:
‘I am stoked & over the moon! Profit made was $27k. This is truly mind blowing.’
Jeff
‘I was amazed when I opened my portfolio last week to see a profit of over $77,000.’
John
‘I am sitting on profits of $21,300 — haha!’
Al
‘So far, I am up in excess of $100,000’
John H.C.
Just look at the winners they’ve banked over the last couple of years:
- MEO Australia: SOLD +220%
- Eastern Corporation: SOLD +138%
- Retail Food Group: SOLD 116%
- McPherson’s Ltd: SOLD +338%
- LNG: SOLD +1,304%
- Bellamy’s Australia: SOLD 575%
- CleanTeQ: SOLD HALF +1,053%
- Collins Foods: SOLD +208
- FAR Ltd: SOLD +166%
Do you know anyone else making profits like these from the stock market? (If you do, then they probably belong to my special circle of investors.)
I’ve been researching this market for a long time. I can show you scores of stocks just like these.
But right now the most urgent of my selections is the ready-to-surge ‘time machine’ medical stock I’ve written to you about today.
Like I’ve said, a calculated $5k stake on this company could potentially make you more than $37k.
These sorts of climbs can be exhilarating. And I should warn you: to some people, it can be unsettling.
You need a bit of nerve to invest this way because you’re racing through the speed limit here. Most people will never see their money move up this fast. It can make them nervous.
But if you think you can handle the pace, you could stand to make a packet...
Then I’d like to make you an offer…
Let me send you my best
stock tips every month
With your permission, I’d like to give you a no-obligation 30-day trial subscription to my newsletter, Australian Small-Cap Investigator.
If you’ve read this far, it's obvious you're interested in making big money from relatively small stakes...you’ve seen what these stocks can do, and you want a taste.
If you’re anything like me, you want to get started — pronto.
Good.
Every month, I’ll send you my research advisory Australian Small-Cap Investigator.
My focus is to find the best small-caps on the ASX. They will come from a breadth of industries, but you will find that there is a technology angle to many of them. That’s because no matter where you look, new technologies are already there.
These small-cap companies with big ideas have the potential to change the world…and transform your financial life.
In Australian Small-Cap Investigator, you’ll get my most urgent small-cap tips, insight on exciting new trends, and my full buy-list of white hot companies on the verge of something spectacular.
I’m not new to this game. I have an extensive background in finance and the financial markets…focusing exclusively on exciting little companies I believe are capable of rapid climbs in price.
If you agree to receive Australian Small-Cap Investigator on a 30-day trial basis, I’ll ensure that you'll get to know about the best small-caps, long before the blokes at Macquarie, UBS, Citigroup and Goldman Sachs pick up the scent...
My aim is for you to have the opportunity to watch your handful of cents potentially multiply many times over from the comfort of your own living room.
And I want to get you started with this URGENT small-cap play…the biotech company on the verge of a landmark partnership deal.
Sound good to you?
Try it out
To make sure Australian Small-Cap Investigator is right for you, I’ve arranged a special trial period for you.
That means you can try it out for a full 30 days under no obligation at all.
If you don’t want to continue receiving my urgent small-cap tips — just let me know within 30 days. You’ll get a full refund AND you can keep your special biotech stock briefing with my compliments.
I just want you to see for yourself what these stocks could do for your money…and your life.
A lot of people who took up this special trial in the past probably had doubts it would be right for them.
But in a very short space of time…they saw the powerful difference investing in the fast-lane could make:
‘Just real quick, I am sitting on profits of $21,300. It is now my biggest position in my 29 stock portfolio. Thank you for the tip.’
Al Cameron
‘A profit of around 900% in under 2 months. Quite amazing...’
Brad
‘A profit of $432, 000. Very, very pleased with my investment. Cheers!’
Vince
I’m certain that each and every one of these readers went into this with a few doubts in their mind…
The point is, you won’t know what this can do for you until you try it yourself.
Get my stock tips for the next
30 days — no strings, no obligation
The moment you start your trial membership, you’ll get clued up on my hottest small-caps to buy now. Here’s what you’ll get:
1. A private password so you can access your urgent briefing ‘Ignition point 2017: How you could make 748% from the ASX medical time machine’.
It contains all my research on the company I’ve told you about today.
Remember, this is an explosive, ready-to-erupt situation. This company could rocket up ANY DAY NOW…when its new tie-up with ‘big pharma’ takes over the newswires…it could be too late for you to get in on the maximum upside.
My advice — as soon as you get your hands on the report, read it immediately.
That way you could be in BEFORE the biggest potential up-move.
You’ll get all the information you need to get in right away. I’ll run you through all the potential risks and rewards so you are fully up to speed.
Then in the next month (and each month after that if you choose to stay on as a subscriber) I’ll send you an easy-to-follow summary of my new and exciting small-cap share tips.
You will receive at least one brand new share tip in each monthly issue.
I’ll explain why I believe each is an under-priced profit opportunity.
Just give me 30 days to show you what we can do.
So far, you’ve only had a cheeky glimpse at this hidden world. But it’s more rewarding than you can even imagine.
And once you start your trial…
2. I’ll also send you a weekly email update
I’ll keep you bang up-to-date on market developments and share any important news on our open positions.
I’ll tell you whether to buy more, sell or hold your position for the time being.
You don’t need to analyse a single balance sheet, and you don’t need to risk a lot of money up front. I do ALL the work.
‘No guesswork’
It’s like subscriber Colin Sherrott says:
‘[You have] taken away more of the guesswork than anything else I have ever tried. So far all the tips that I have followed have been spot on.’
It’s not easy to lock on to stocks that could quadruple your stake in a matter of months — sometimes weeks…
That’s why every single stock I consider goes through a strict period of dedicated financial analysis.
Basically, I ask myself four very important questions:
1. Do I FULLY understand the business?
First off, I need to know the business inside out. Beyond all the dry technical data (which is important) I get stuck into how the business is run, talk to the management…all to get a real, genuine understanding of the company's core activity. Whenever possible, I pay a personal visit.
When I’m happy that I’ve got the industry and the company itself sussed-out, do I ask myself this:
2. Do I TRUST the guys at the top?
Put it this way, would you bet on the Hawthorn next season if they put some clown in charge of the team? Of course not. Like a footy team, a company is only as good as the people at the top. If I come across a company with a world-changing idea but that is run by buffoons I don’t have faith in, you’ll never hear about that company from me.
If they tick all my boxes, then I can move on to my next question…
3. Am I looking at a future household name?
That’s important. You can make OK returns on companies that skulk in the shadows for decades. But for me, that’s not good enough. I’m looking for the next Google, PayPal, Netflix, Coca-Cola…companies that eventually become familiar to almost everyone in the world.
And I’m looking for them right here in Australia – a market that’s going to receive billions of foreign capital… all hitting the smallest, most innovative companies we have to offer. That is going to give them a huge edge over competitors. Do not be surprised if the next wave of world changing companies comes from right here.
If I’m happy I’m on to something big, I can finally ask:
4. Do the numbers stack up?
OO, this is the most boring part! But you simply cannot underestimate the importance of old-fashioned number-crunching in identifying good small stocks. No matter how great a company's product or service is...no matter how adept their PR company at spinning a compelling story or promising a stellar future...the balance sheet doesn't lie. I have a lot of experiencing in analysing small companies and I know what I’m looking for.
I'll send you a complete rundown on how I identify my picks - for free - as part of the package you can claim the moment you become an Australian Small-cap Investigator trial member.
If that sounds good to you, click here now to start your no-obligation 30 day trial.
But that’s not all...
Trial Australian Small-Cap Investigator for the next 30 days and you’ll also receive:
● ‘Small-Cap Dynamic Stock Analysis’
This report explains my stock picking strategy.
Inside I reveal everything I look for in a small-cap stock in precise detail, including a complete breakdown of how I determine whether any one stock is worth a punt.
On top of that, I’ll throw this in:
● ‘Investor’s Starter Guide 2017’
This short guide answers the most essential questions beginners have about buying and selling shares.
You’ll learn how to place orders with your broker...which type of brokerage is right for you...the importance of using limit orders...how much to invest…and much more.
But that’s not all — start your trial today and you’ll also get:
● ‘The Secrets of Spotting Small-Cap Value’
This easy-read guide will give you a grasp of the essential tools for evaluating any share...including P/E ratios, yield, net asset value, free cash flow and more.
Plus it reveals many secrets behind my highly profitable share risk-rating system.
Don’t worry — you don’t really need any of this. I’ll do everything for you. But this just explains exactly how I go about my analysis.
There’s something else you’ll get too — again, complimentary and yours to keep forever:
● ‘How Creative Destruction Works To Make Small-Cap Investors’ Rich’ ’
If you can identify and back the companies led by talented entrepreneurs driving new inventions, technologies and discoveries...you stand to do very well.
There hasn’t been time to go into this side of my research today...but it’s waiting for you in the weeks ahead. I’ve spent the last decade of my life researching breakthrough companies. Everything you need to know on how to turn ground-breaking ideas into potential high-profit stock plays is here in this complimentary report.
Again, all these reports are yours to keep, whether you decide to continue your subscription after your trial or not.
I think that’s a fair deal. And if you can see the potential here, don’t sit it out. Take me up on it!
Remember, you’re just giving this a try.
Claim your 30 day no obligation trial subscription of Australian Small-Cap Investigator today and you will have instant access to your first issue and special reports.
Take a look at the recommendations inside.
Study the analysis.
If you’re not ready to jump in and invest yet, that's fine. You can ‘paper trade’ all of the tips during your 30 day trial to see the money-making potential for yourself.
If, after watching the shares progress, you can’t see yourself making any real profits with my small-cap strategy — no worries.
Just get in touch in the first 30 days and I'll refund every last cent of your subscription fee. No questions asked.
And, just for giving this a go, you can keep your bonus stock briefing on the biotech time machine firm. That’s yours, whatever you decide.
Right about this time, you’re probably wondering…
What will you pay if you
decide to stick around?
**HALF PRICE DEAL**
$99 per year.
Let me put that into context for you: I know some fund managers who charge that for 10 MINUTES consultancy.
My share tip advisory service works out at about 27 cents A DAY.
Dollar for dollar, I believe this is the best small-cap research you’ll find in Australia.
When you consider the upside potential of the small-cap stock I’ve shown you today…and when you look at the profits I’ve made for my readers over the last few years…
I think that $99 seems like a pretty good deal.
But I’d like to make this deal even sweeter...
I’d like offer you an introductory price of just $49 for the first year — provided you respond now.
That’s a HALF-PRICE DISCOUNT.
I think you’ll agree, this is a terrific deal. Especially when you consider the amount of money you could make from ready-to-surge small-cap stocks.
And I’ve priced it this way because I do not want ANY barrier between you and the big money you could make from small, turbo-charged stocks.
I’ve reduced the price to $49 for the first 12 months (and $99 a year thereafter) so that the cost is not an issue for you. If you see the potential here — I don’t want to stand in your way.
This is my way of letting the regular bloke make the same kind of money as fee-guzzling fund managers.
In fact, we could likely make many times more than even the best fund managers out there.
After your first year, the price will automatically revert to $99 a year. That’s incredible value. Don’t worry, when your first 12 months is coming to an end, you’ll get a reminder email. My sole aim is to put you in a position to make money — not worry about subscription fees.
That’s what Australian Small-Cap Investigator is all about. Everyone should have a shot at making their fortune on the stock market. As you can see, we’re making it happen for thousands of regular Aussies. And you could be the next person to pocket three, four or five times your money.
My advice?
Click here now to take a 30-day no-obligation trial of Australian Small-Cap Investigator, and everything you’ve read about here is yours for less than the cost of dinner for two at a half-decent restaurant.
You are not risking a penny in subscriptions to give this a try for 30 days.
But I think there is a huge cost to you passing up this chance to get in early on Australia’s rising star companies.
Don’t sit this one out!
Today you have the chance to
make life-changing money
Will you take it?
You’ve seen the profits Australian Small-Cap Investigator has made for investors like you.
We’ve closed out on positions for returns of 338%, 1304%, 208%, 1053% (to name just a few).
You’ve seen the gains in my open buy-list — huge winners that could turn a small stake into an unforgettable holiday…a new car…even a new family home.
And I’ve shown you everything you need to know about the partnership that I’m predicting could send a revolutionary Aussie biotech firm on a nosebleed climb.
I’ve done all I can to show you why I’m so excited and confident about this stock’s chances of making a 748% leap in price…
And why the situation is so urgent!
Remember, an announcement about their project with the biggest pharma firm in the world could trigger a raging upsurge…wait this out and you could be locked out of the maximum upside.
Download your complimentary report as soon as you can: ‘Ignition point 2017: How you could make 748% from the ASX medical time machine’
Get in today and you cancel out the risk of this roaring up in price without you.
It’s your choice.
I look forward to welcoming you very soon.
Best regards,
Sam Volkering,
Editor, Australian Small-Cap Investigator
PS: If you still don’t think it’s possible to make five, six, even 10 times your money from a single investment…consider this:
Over the last few years, thousands of people like you have used small-cap stocks that I’ve recommended to help them bank astronomical amounts of money. Not just once or twice – but repeatedly.
Jim Gogos from Auckland is one of those people. He wrote in to say:
‘You blokes should be thrown in a harem of a dozen nymphomaniacs and made to suffer the consequences!
‘I bought the [xxx] stock for $10,000 at .21c one year ago, thanks to your good diligence!
‘As of today I'm up $117, 000 profit, the stock is up 1,076 %.
‘I’m starting to think about retirement or buying a cottage in a Greek fishing village, my origins.
‘I do feel this stock has a lot more steam, maybe another 1000 % or even 10,000!
‘Many, many thanks!’
And that letter wasn’t a one-off... an increasing number of ambitious investors have banked rapid-fire profits:
‘I just wanted to say I have a super smile on my face with your tips… About a $70k gain in the last month is an estimate.’
Lawrie
‘There is no doubt that you acquired a God-like power to determine which shares move.’
Stan G
‘I am up well over $50k at present. Your selection of shares has been remarkable. You have achieved this in a very unstable market. Well done.’
Euan
‘I’m up $50K since subscribing’
Bryan Milner
‘I made $70,000 in only a few weeks. I have also made other gains’
B. McMonagle
These punters have made a packet from Australian Small-Cap Investigator — why not you?